What is the impact of type 2 diabetes mellitus on CYP450 metabolic activities? DOI Open Access
Brian Tomlinson, Yanhong Li

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2023, Volume and Issue: 19(12), P. 867 - 870

Published: Nov. 24, 2023

KEYWORDS: cytochrome P450 (CYP)CYP2C19nonalcoholic fatty liver diseasenonalcoholic steatohepatitisobesitytype 2 diabetes

Language: Английский

Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review DOI Creative Commons
Basma Hossam Abdelmonem,

Noha M. Abdelaal,

Eman K. E. Anwer

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(7), P. 1467 - 1467

Published: July 2, 2024

Cytochrome P450 (CYP450) is a group of enzymes that play an essential role in Phase I metabolism, with 57 functional genes classified into 18 families the human genome, which CYP1, CYP2, and CYP3 are prominent. Beyond drug CYP metabolize endogenous compounds such as lipids, proteins, hormones to maintain physiological homeostasis. Thus, dysregulation CYP450 can lead different endocrine disorders. Moreover, significantly contribute fatty acid cholesterol synthesis, bile biosynthesis, impacting cellular physiology disease pathogenesis. Their diverse functions emphasize their therapeutic potential managing hypercholesterolemia neurodegenerative diseases. Additionally, implicated onset development illnesses cancer, influencing chemotherapy outcomes. Assessment enzyme expression activity aids evaluating liver health state differentiating between diseases, guiding decisions, optimizing efficacy. Understanding roles clinical effect genetic polymorphisms crucial for developing personalized strategies enhancing responses patient populations.

Language: Английский

Citations

18
TransformEHR: transformer-based encoder-decoder generative model to enhance prediction of disease outcomes using electronic health records DOI Creative Commons
Zhichao Yang, Avijit Mitra, Weisong Liu

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Nov. 29, 2023

Abstract Deep learning transformer-based models using longitudinal electronic health records (EHRs) have shown a great success in prediction of clinical diseases or outcomes. Pretraining on large dataset can help such map the input space better and boost their performance relevant tasks through finetuning with limited data. In this study, we present TransformEHR, generative encoder-decoder model transformer that is pretrained new pretraining objective—predicting all outcomes patient at future visit from previous visits. TransformEHR’s framework, paired novel objective, helps it achieve state-of-the-art multiple tasks. Comparing model, TransformEHR improves area under precision–recall curve by 2% ( p < 0.001) for pancreatic cancer onset 24% = 0.007) intentional self-harm patients post-traumatic stress disorder. The high predicting shows potential building effective intervention systems. also generalizable be easily finetuned

Language: Английский

Citations

36
The Global Epidemic of Metabolic Fatty Liver Disease DOI

Ethan C. Z. Lee,

Vickram Vijay Anand,

Alex C. Razavi

et al.

Current Cardiology Reports, Journal Year: 2024, Volume and Issue: 26(4), P. 199 - 210

Published: Feb. 20, 2024

Language: Английский

Citations

15
Intermittent fasting regimens for metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis of randomized controlled trials DOI
Mohamed Abuelazm, Islam Mohamed,

Ahmed Naeem

et al.

European Journal of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 36(4), P. 371 - 381

Published: Feb. 23, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by excessive hepatic fat accumulation. Intermittent fasting (IF) has emerged as potential therapeutic strategy with the ability to induce weight loss, improve insulin sensitivity and reduce steatosis. We aim compare efficacy of different IF regimens for MASLD management. A systematic review network meta-analysis randomized controlled trials investigating MASLD. PubMed , EMBASE WOS SCOPUS Cochrane Central Register Controlled Trials were searched until 10 April 2023. Analysis was performed using R software meta netmeta packages. Mean difference (MD) used pool continuous outcomes 95% confidence intervals (CIs). Our registered in PROSPERO (CRD42023418467). included eight total 635 participants. The 5 : 2 diet significantly improved stiffness (MD, -0.32; CI, -0.55 -0.09; P < 0.01). Time-restricted feeding steatosis (controlled attenuation parameter score) -39.83; -64.78 -14.87; No significant changes observed asparate aminotransferase, gamma-glutamyl transpeptidase, low-density lipoproteins cholesterol, triglyceride levels, basal index, blood pressure, Homeostatic Model Assessment Insulin Resistance, sugar, lean body mass or waist circumference across all regimens. However, alternate-day showed positive results anthropometric measures, including improvements mass, circumference, reduction ( 0.05). various effects on clinical patients; however, these not consistent. Therefore, patient-tailored regimen should be considered.

Language: Английский

Citations

7
Drug‐Induced Liver Injury in Patients With Chronic Liver Disease DOI Creative Commons
Marwan Ghabril, Raj Vuppalanchi, Naga Chalasani

et al.

Liver International, Journal Year: 2025, Volume and Issue: 45(3)

Published: Feb. 10, 2025

ABSTRACT Objective Drug‐induced liver injury (DILI) is a global problem and can develop from exposure to prescription or over‐the‐counter medications as well herbal dietary supplements. The diagnosis of DILI clinically challenging, be severe leading failure, death, transplantation. Patients with underlying chronic diseases (CLD) may at increased risk for DILI, which associated factors related drug disease. Methods This review summarises current knowledge on the outcomes in patients CLD. Results CLD an DILI. Additionally are more worse after Discussion poor accentuated potentially worst‐case scenario acute‐on‐chronic failure. We highlight key observations broad range high‐DILI agents implicated those populations.

Language: Английский

Citations

0
Possible Role of Platelets in the Development and Progression of Non-Alcoholic Fatty Liver Disease DOI Creative Commons
А.Ф. Шептулина, Ekaterina Liusina, Olga A. Zlobovskaya

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2025, Volume and Issue: 30(3)

Published: March 17, 2025

To date, an increasing body of evidence supports the potential role activated platelets in pathogenesis non-alcoholic fatty liver disease (NAFLD). This is likely due to their ability secrete biologically active substances that regulate regeneration processes, ensure hemostasis, and participate immune response. Additionally, several studies have demonstrated efficacy antiplatelet agents reducing inflammation, severity fibrosis, progression fibrosis steatohepatitis (NASH). Since NAFLD not independent indication for therapy, primary regarding has been derived from using animal models or patients with concomitant cardiovascular diseases. narrative review will discuss main functions platelets, unique interactions cells, outcomes these interactions, as well results evaluating safety therapy NAFLD.

Language: Английский

Citations

0
Uncovering hepatic transcriptomic and circulating proteomic signatures in MASH: A meta-analysis and machine learning-based biomarker discovery DOI
Elena Cristina Rusu,

Helena Clavero‐Mestres,

Mario Sánchez-Álvarez

et al.

Computers in Biology and Medicine, Journal Year: 2025, Volume and Issue: 191, P. 110170 - 110170

Published: April 12, 2025

Language: Английский

Citations

0
Fructose aggravates copper-deficiency-induced non-alcoholic fatty liver disease DOI
Xin Jiang, Ruixiang Hu,

Yipu Huang

et al.

The Journal of Nutritional Biochemistry, Journal Year: 2023, Volume and Issue: 119, P. 109402 - 109402

Published: June 11, 2023

Language: Английский

Citations

9
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension DOI Creative Commons
Oleksandr Petrenko, Philipp Königshofer, Ksenia Brusilovskaya

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(3), P. 109301 - 109301

Published: Feb. 20, 2024

Persistent liver injury triggers a fibrogenic program that causes pathologic remodeling of the hepatic microenvironment (i.e., fibrosis) and portal hypertension. The dynamics gene regulation during disease progression early regression remain understudied. Here, we generated transcriptome profiles in two well-established models at peak fibrosis spontaneous after removal inducing agents. We linked key readouts, such as pressure, collagen area, transaminase levels, to differentially expressed genes, enabling identification transcriptomic signatures progressive vs. regressive These candidate biomarkers (e.g.,

Language: Английский

Citations

3
miR-27b targets MAIP1 to mediate lipid accumulation in cultured human and mouse hepatic cells DOI Creative Commons

Eiko Sakai,

Tsutomu Imaizumi,

Ruruka Suzuki

et al.

Communications Biology, Journal Year: 2023, Volume and Issue: 6(1)

Published: June 24, 2023

Non-alcoholic liver disease (NAFLD) is a condition caused by excessive fat accumulation in the and developed via multiple pathways. miR-27b has been suggested to play crucial roles development of NAFLD, assuming targeting genes involved lipid catabolism anabolism. However, other pathways regulated are largely unknown. Here we show that was induced miR-27b-transfected human mouse hepatic cells knockdowns three miR-27b-target genes, β-1,4-galactosyltransferase 3 (B4GALT3), matrix AAA peptidase interacting protein 1 (MAIP1) PH domain leucine rich repeat phosphatase 2 (PHLPP2), accumulation. We also B4GALT3 MAIP1 were direct targets overexpression ameliorated miR-27b-induced In addition, Maip1 expression declined mice fed high-fat diet, suggesting involvement decreased fatty liver. Overall, identified MAIP1/miR-27b axis as mediator accumulation, potential therapeutic target for NAFLD.

Language: Английский

Citations

8